Profit margins, US medicine supplies may get hit: Biocon
Biocon anticipates potential challenges from proposed US tariffs on pharmaceutical imports, which could squeeze profit margins and affect the affordability of generic medicines. With the US being its largest market, Biocon is strategizing to navigate the impact, considering factors like tariff rates and competitor responses. The company is also focusing on expanding its presence in Europe to mitigate risks.🕒 1 min read
Biocon anticipates potential challenges from proposed US tariffs on pharmaceutical imports, which could squeeze profit margins and affect the affordability of generic medicines. With the US being its largest market, Biocon is strategizing to navigate the impact, considering factors like tariff rates and competitor responses. The company is also focusing on expanding its presence in Europe to mitigate risks.
Continue Reading
- Why Storing Mangoes In That Blinkit Bag Is A Smart Choice For Summer
- Maharashtra Common Entrance Test 2026 Schedule Out, Check details
- Watch: At This Viral Cafe, Your Coffee Is Flown Down In An Air Balloon
-
‘He must be looked after and respected’: Ganguly backs appeal for Imran Khan
- Why US Wants Access To All Social Media Accounts Of Visa Applicants: Explained
- Bull Charges At Gujarat Man, Continues Attack Till Locals Step In For Rescue
-
Japanese PM Sanae Takaichi’s Party Secures Landslide Victory In Snap Polls
-
India vs England LIVE, 3rd Test Day 2: Shubman Gill, Mohammed Siraj’s Argument With Umpire Reignites Ball Controversy; England 8 Down
- Sooryavanshi carnage bamboozles South Africa U19s with 63-ball ton
-
Gold & silver price prediction today: MCX Gold to remain bullish? Here’s the outlook